Vemurafenib Completed Phase 2 Trials for Malignant Melanoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01378975A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases
NCT01253564A Study of RO5185426 in Previously Treated Melanoma Patients With Brain Metastases
NCT01248936A Study of RO5185426 in Patients With Metastatic Melanoma